S-methyl-L-cysteine Protects against Antimycin A-induced Mitochondrial Dysfunction in Neural Cells via Mimicking Endogenous Methionine-centered Redox Cycle*

Lan NI1,3,4, Xin-lei GUAN1,2, Fu-feng CHEN1, Peng-fei WU1,3,4#
1Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Pharmacy, Wuhan Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430033, China
3Tongji-Rongcheng Center for Biomedicine, Wuhan 430030, China
4Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan 430030, China
© The Author(s) 2020

Summary: Mitochondrial superoxide overproduction is believed to be responsible for the neurotoxicity associated with neurodegeneration. Mitochondria-targeted antioxidants, such as MitoQ, have emerged as potentially effective antioxidant therapies. Methionine sulfoxide reductase A (MsrA) is a key mitochondrial-localized endogenous antioxidative enzyme and it can scavenge oxidizing species by catalyzing the methionine (Met)-centered redox cycle (MCRC). In this study, we observed that the natural L-Met acted as a good scavenger for antimycin A-induced mitochondrial superoxide overproduction in PC12 cells. This antioxidation was largely dependent on the Met oxidase activity of MsrA. S-methyl-L-cysteine (SMLC), a natural analogue of Met that is abundantly found in garlic and cabbage, could activate the Met oxidase activity of MsrA to scavenge free radicals. Furthermore, SMLC protected against antimycin A-induced mitochondrial membrane depolarization and alleviated 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity. Thus, our data highlighted the possibility for SMLC supplement in the detoxication of mitochondrial damage by activating the Met oxidase activity of MsrA.

Key words: methionine sulfoxide reductase A; Met oxidase; S-methyl-L-cysteine; neurotoxin; 1-methyl-4-phenylpyridinium

Reactive oxygen species (ROS), especially the free radicals, are implicated in the toxic mechanism of neurotoxins, including rotenone[1–3], lipopolysaccharide[4] and 1-methyl-4-phenylpyridinium (MPP+) [5], etc. Mitochondria are key cell organelles that control many processes by maintaining energy production. To produce energy, the mitochondrial electron transport chain is coupled with the production of ROS, such as superoxide anion or hydrogen peroxide. Mitochondrial superoxide overproduction is considered to be the major factor in oxidative toxicity associated with neurodegeneration. Mitochondria-targeted antioxidants, such as MitoQ and mitotempo, have emerged as potentially effective antioxidant therapies[6–8]. However, mounting evidence indicates that the mitochondrial ROS are related with multiple essential cellular functions[9, 10] and these mitochondria-targeted antioxidants may disrupt physiological signaling[11, 12].

As a result of the constant production of ROS, mitochondria are protected by various antioxidant systems, such as glutathione reductase, thioredoxin reductase and manganese superoxide dismutase[13]. These antioxidant systems only diminish overproduced mitochondrial ROS, but not affect ROS signaling apt for physiological signaling. The thiomethyl group that exists on the surface exposed methionine (Met) residues has been recognized as a key endogenous antioxidant defense[14–17]. Methionine in proteins is often thought to be a generic hydrophobic residue on the surface. A variety of ROS react with Met residues to form methionine sulfoxide (MetO), which is followed by MetO reductases-mediated reduction back to Met,
named Met-centered redox cycle (MCRC)\[^{15, 17}\]. As a key member of MetO reductases, MetO reductase A (MsrA) has been reported to be abundantly localized in the mitochondrion\[^{18–20}\]. MsrA repairs oxidative damage of proteins and increases resistance of cells against many toxins, including zinc, hydrogen peroxide, 6-hydroxydopamine and acacetaminophen\[^{21–25}\]. MsrA also reduces mitochondrial ROS levels in response to insults\[^{24, 26}\] and protects mitochondrial dysfunctions in a mouse model of Alzheimer’s disease (AD)\[^{27}\]. Although its action via repairing oxidized proteins is easily accepted, the mechanism by which MsrA scavenges ROS remains largely elusive. MsrA has historically been considered a reductase, not an ROS scavenger, for the reaction of Met with oxidizing species was widely viewed as a natural process. Recent studies from our lab have indicated that the antioxidant capability of MsrA may involve a Met oxidase activity that facilitates the reaction of Met with ROS, which may underlie the effect of MsrA on neuroinflammation and lifespan\[^{28, 29}\].

Exogenous substrates like L-methionine (L-Met) could activate the Met oxidase activity\[^{29}\], but dietary supplementation with L-Met is not applicable for mitochondrial dysfunction, because Met is rapidly incorporated into protein or metabolized, and high dietary Met intake confers an increased risk of acute coronary events in patients with cardiovascular diseases\[^{30, 31}\]. S-methyl-L-cysteine (SMLC) is a hydrophilic cysteine-containing compound naturally found in Alium plants such as garlic and onion\[^{32}\]. Previous studies reported its safety and benefits, including no adverse effect and toxicity in mammals, lowering of the serum cholesterol level, a delay in diabetes pathogenesis and prevention in PD symptoms\[^{33–36}\]. Furthermore, SMLC has been revealed as a substrate in the catalytic antioxidant system mediated by MsrA\[^{36}\]. In the present study, we found that SMLC protected against antimycin A-induced mitochondrial dysfunction in neural cells via activating Met oxidase activity of MsrA and mimicking endogenous Met-centered redox cycle.

1 MATERIALS AND METHODS

1.1 Chemicals and Materials

Dulbecco’s modified Eagle’s medium (DMEM), horse serum, fetal bovine serum and G418 were purchased from Gibco Invitrogen Corporation (USA). Trypsin, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (USA). Plasmid containing rat MsrA cDNA (pcDNA3.1-rMsrA) was provided courtesy of Dr. Bertrand Friguet of the Université Paris 7-Denis Diderot. L-Met, SMLC and dithiothreitol (DTT) were purchased from Sigma-Aldrich (USA). All the other reagents were of analytical grade. Amicon ultra-4 centrifugal filter devices were purchased from Millipore Carrigtwohill, Co. Cork (Ireland). H\(_2\)O\(_2\) was purchased from Merck (Germany). All the chemicals were dissolved in water to make individual stock solutions, depending upon their water solubility, and stored at \(-20^\circ\text{C}\). Other general agents were available commercially. Distilled water was deionized in a Milli-Q SP reagent water system (Millipore, USA).

1.2 Preparation of Rat Recombined MsrA

The rat recombined MsrA was prepared and purified from \textit{E. coli} BL21, as described in our previous report\[^{37}\]. In brief, MsrA coding region was ligated into the restricted pET-32a (+) vector using phage T4 DNA ligase, and BL21 cells were transformed with the recombinant plasmid and grown in LB medium. The cells were harvested, and applied to a Ni-Trap nickel-chelating column. The N-terminal His-tag of recombinant protein was removed using a Thrombin kit. The activity of recombinant MsrA was monitored by detecting both total MetO reducing activity and methyl sulfoxide-initiated oxidation of DTT.

1.3 Electron Paramagnetic Resonance (EPR)

EPR was performed as described in our previous reports with some modifications\[^{28, 29}\]. DMPO was used as a free radical trapper. EPR signals were detected with a Bruker e-scan EPR spectrometer (Burker, Germany). We produced hydroxyl radical (OH\(^-\)) by the Fenton reaction in the mixture of 0.25 mmol/L \(\text{H}_2\text{O}_2\) and 0.1 mmol/L \(\text{Fe}\text{SO}_4\) in the presence of 0.1 mmol/L DMPO. The spin traps, L-Met (0.1 or 1 mmol/L), SMLC (0.1, 1 or 10 mmol/L) and rMsrA/non-active rMsrA (1 \(\mu\text{mol/L}\)) were added before the Fe (II) and \(\text{H}_2\text{O}_2\). Samples (20 \(\mu\text{L}\)) were loaded into a quartz tube and the EPR spectra were recorded at room temperature. The EPR microwave power was set at 4.88 mW. The modulation frequency was 9.76 GHz. The time constant was 81.92 ms. The conversion time was 81.92 ms and a sweep time of 41.94 s was used. Each sample was scanned once. A sweep width of 100 G was used for experiments with DMPO. The receiver gain was set at \(3.17 \times 10^3\). Simulation and fitting of the EPR spectra were performed using the Bruker WinEPR program.

1.4 Cell Cultures and Treatment Paradigm

Cells were cultured as described in our previous reports with slight modifications\[^{37, 38}\]. Rat PC12 cells were obtained from Chinese Type Culture Collection and have been differentiated to be neuron-like by treating with nerve growth factor. PC12 cells were cultured in DMEM containing 5% heat-inactivated fetal calf serum, 10% heat-inactivated horse serum, 100 \(\mu\text{g/mL}\) streptomycin and 100 U/mL penicillin in a humidified atmosphere of 95% air and 5% \(\text{CO}_2\) at 37\(^\circ\text{C}\). The culture medium was changed and the cells were passaged by trypsinization every 3 to 4 days. For
oxidative stress, cells were rinsed twice with PBS and subjected to H$_2$O$_2$ (250 μmol/L) in DMEM. Different concentrations of L-Met were added to the culture medium 12 h prior to oxidative stress until the end of H$_2$O$_2$ treatment.

The human dopamine neuronal cell line, SH-SY5Y, was obtained from Cell Centre of Chinese Academy of Medical Sciences (China) and cryopreserved after subculturing various passages. Each subculture was limited to no more than 10 passages. SH-SY5Y cells (passages 30–40) were cultured in DMEM/F12 medium containing 10% heat-inactivated FBS, 50 U/mL penicillin and 50 mg/mL streptomycin in a humidified atmosphere of 95% air and 5% CO$_2$ at 37°C. Medium was changed every 2 days, and cells were passaged at 80% confluence every 3–4 days. In the experiments, cells were synchronized at the G0 phase by serum deprivation. Different concentrations of L-Met and SMLC in DMEM/F12 medium without FBS were used to treat SH-SY5Y cells for 12 h. After preconditioning, a final concentration of MPP$^+$ (2 mmol/L) was used to treat SH-SY5Y cells for 48 h. MPP$^+$ treatments were performed in DMEM/F12 medium without FBS under dark condition to avoid phototoxicity decomposition reaction.

1.5 ROS Staining

The total intracellular ROS were determined by the MitoSOX red assay. In brief, PC12 cells were seeded in a 6-well plate and loaded with MitoSOX red (Invitrogen, USA) for 1 h, which was followed by pretreatment with L-Met (0.1, 0.5, and 1 mmol/L) or SMLC (0.1, 0.5, and 1 mmol/L) for 30 min, and then treatment with antimycin A (100 ng/mL) (Sigma-Aldrich, USA). After incubation at 37°C for 30 min, the fluorescence images were immediately taken using a fluorescence microscope (System Microscopy IX70; Olympus, Japan). For the detection of cellular superoxide, we used 5 μmol/L MitoSOX (Invitrogen, USA), and took images using excitation and emission filters of 543 and 565 nm, respectively. Fluorescent signals intensities of cells were obtained using Image-Pro Plus (IPP) software.

1.6 Construction of Short Hairpin RNA (shRNA) Lentiviral Expression Vector and MsrA Knockdown

shRNA lentiviral expression vector was constructed as described in our previous reports with some modifications[29]. A third generation of self-inactivating lentivirus vector (GeneChem, China) containing a CMV-driven GFP reporter and a U6 promoter upstream of the cloning sites (EcoRI and AgeI) was used for cloning MsrA shRNA. The target sequence for control scrambled shRNA was 5′-TTCTCCGAACGTGTCACGT-3′ and rat MsrA was 5′-AGCACGTACGTTGAGGA-3′. PC12 cells were infected with lentivirus at a multiplicity of infection (MOI) of 20 for 10 h. Then, the medium was replaced with fresh complete medium. After 72 h, cells were observed under the fluorescence microscope to confirm that more than 80% of cells were GFP-positive. The knockdown of MsrA was evaluated by Western blotting.

1.7 Mitochondrial Membrane Potential

To determine the mitochondrial membrane potential, PC12 cells were seeded in a 6-well plate and incubated with 2 μg/mL JC-1 at 37°C for 30 min, which was followed by pretreatment with L-Met (1 mmol/L) or SMLC (1 mmol/L) for 30 min, and then treatment with antimycin A (100 ng/mL). After incubation at 37°C for 30 min, cells were then washed twice with PBS and immediately examined by fluorescence spectrometry using a fluorescence microplate reader (System Microscopy IX70; Olympus, Japan). A 488 nm filter was used for excitation of JC-1, and emissions at 535 and 595 nm were used to quantify the population of mitochondria with green (JC-1 monomers) and red (JC-1 aggregates) fluorescence respectively. The red/green ratio was used to reflect the mitochondrial membrane potential.

1.8 MTT Assay

Cell viability was measured by MTT assay based on the conversion of MTT to formazan crystals by mitochondrial dehydrogenases. In live cells, mitochondrial enzymes have the capacity to transform MTT to insoluble formazan. Cell cultures were incubated with MTT solution (5 mg/mL) for 4 h at 37°C. Following this, the medium was discarded and DMSO was added to solubilize the reaction product formazan by shaking for 15 min. Absorbance at 492 nm was measured with a microplate reader (ELx800, Bio-Tek, USA). Cell viability of vehicle-treated control group was defined as 100%. Cell viability was expressed as a percentage of the value in control cultures.

1.9 MsrA Homology Modeling

MODELLER suite (version 9.11, Sali & Blundell 1993) was used to construct the model of rat MsrA, and the template was a known complex of Met sulfoxide reductase A from Neisseria meningitides (PDB ID 3BQF) as described previously[29]. Then residue CY72 of MsrA was modified to its oxide state, just called CYO72 here, and the modified-MsrA was named CYO72-MsrA for convenience. The coarse model of CYO72-MsrA was then refined by a 12 ns standard molecular dynamics in AMBER 12 (Case 2012b) until the ensemble attained its equilibrium state to get the stable conformation of CYO72-MsrA. During the molecular docking process, the CYO72-MsrA was solvated in a truncated octahedron box with 0.1 mol/L NaCl and several another Na$^+$ ions added to counter solute charges. L-Met was prepared with academic maestro 9.6 from DESMOND molecular dynamics suite and minimized energetically for further studies. According to the known crystal structure of
MsrA (PDB ID 3BQF), all of the ligands were docked manually to the active site of CYO72-MsrA to form various complexes, and the S-Me group was consistent with that of 3BQF structure. Again, all of complexes were refined in AMBER 12 with explicit solvent environment and the same ion strength mentioned above. After that, the ligands were pulled 16 angstroms away from the active site to obtain the starting structures for later Steered Molecular Dynamics simulations.

To distinguish the difference of action between ligands and CYO72-MsrA, steered molecular dynamics (SMD) method was conducted for those starting structures prepared above. First, those structures were solvated with similar conditions as described before. One minimization was then done with restraint on solutes following one non-restraint minimization to get rid of steric clashes inside the ensembles. Next, all of those systems were heated within 200 ps from 0 K to 300 K with weak restraints on solutes to prevent ligands shifting away from enzyme. After heating those systems completely, NVT simulations were arranged to all systems at 300 K. All of NVT simulations were sustained for a longer period of 10 ns with time step 2 fs and 5 000 000 steps allegre. Finally, several one-ns SMD simulations were performed for every ligand, and they pulled the ligands into the active site of CYO72-MsrA from 16 angstroms to their own equilibrated states of complexes. In the meantime backward pulling simulations were done to pull ligands away from the active site of CYO72-MsrA. The forward and backward works of pulling vs. a series distances could be figured for later analysis. All of MD simulations described here were completed in Amber 12 (Case 2012a) with CYO72-MsrA parameterized using the Amber 99SB-ildn force field[39]. CYO72, which represents the oxidized form of Met, was parameterized with antechamber of Amber suites by using the GAFF force field and the charges of all non-standard residues including CYO and L-Met were calculated from an ORCA 2.8 quantum chemistry program package from the development team at the University of Bonn. Structure was optimized at the HF/6-31 g (d) level of theory (Neese. 2010). Spin-restricted Kohn-Sham determinants were chosen to describe the closed-shell wave functions, employing the resolution of identity (RI) approximation and the tight self-consistent field (SCF) convergence criteria provided by ORCA. In addition, some calculations were conducted in parallel on GTX 690 GPU or 3.2G multi-core Xeon 5580 CPU to accelerate the processes of simulations.

1.10 Statistical Analysis
Data were expressed as means±standard deviation (SD). Comparison between two groups was evaluated by the unpaired Student’s t-test. Multiple comparisons were tested by one-way analysis of variance (ANOVA) followed by Duncan’s multiple-range test. Differences were considered significant at P<0.05.

2 RESULTS
2.1 L-Met Reduces Antimycin A-induced Superoxide Generation in PC12 Cells via a MsrA-dependent Mechanism
We induced O2-· production in PC12 cultured cells by a mitochondrial respiratory complex III inhibitor, antimycin A, as previously described[29]. Antimycin A increased levels of O2-·, which were judged by the fluorescence signals emitted by the oxidized forms of Mito-SOX (fig. 1). Bath application of antimycin A (100 μg/mL) for 0.5 h induced an increase of ROS level to 320%±42% of control group (n=9, P< 0.01 vs. blank control), which could be alleviated by co-incubation

Fig. 1 L-Met reduces antimycin A-induced superoxide generation in PC12 cells.
PC12 cells were pretreated with 0 (A, B), 0.1 (C), 0.5 (D), or 1 mmol/L L-Met (E) for 30 min and then incubated with vehicle (A) or antimycin A (B-E, 100 μg/mL for 30 min). The levels of superoxide were detected with MitoSOX red. Scale bars represent 100 μm. The fluorescence intensity of superoxide was determined (F). **P<0.01 vs. control group, ***P<0.01 vs. antimycin A group
with L-Met. L-Met (0.1, 0.5 and 1 mmol/L) reduced the superoxide level to 291%±21%, 230%±21% and 174%±22% of control group, respectively (n=6, P<0.01 vs. model, one way ANOVA, fig. 1).

To explore whether MsrA is necessary for antioxidant activity of L-Met, we knocked down the MsrA expression in the PC12 cells. After treatment with lentiviral-expressed specific shRNAs against MsrA, the MsrA expression levels were significantly decreased. The effect of L-Met (1 mmol/L) on antimycin A-induced superoxide increase in the PC12 cells was abolished, suggesting that MsrA is essential for the anti-oxidant activity of L-Met in cells (fig. 2A and 2B; 201%±19% of control group in L-Met with scrambled shRNA group vs. 337%±32% in vehicle with scrambled shRNA group; 357%±34% in L-Met with MsrA shRNA group vs. 325%±41% in vehicle with MsrA shRNA group).

![Fig. 2](https://example.com/fig2.png)

**Fig. 2** L-Met reduces antimycin A-induced superoxide generation in PC12 cells via a MsrA-dependent mechanism.

A, B: PC12 cells were transfected with scramble shRNA (A) or MsrA shRNA (B). The transfected cells were pretreated with vehicle (a–c) or L-Met (d, 1 mmol/L for 30 min) and then incubated with antimycin A (c, d, 100 μg/mL for 30 min). The release of superoxide was determined by the mitoSOX red fluorescence. And the fluorescence intensity of mitoSOX red was calculated in the statistics. Data are expressed as means±SD (n=6–9), **P<0.01 vs. control group, ##P<0.01 vs. model group, or vs. untreated L-Met with scrambled shRNA group.

2.2 MsrA Enhances the Radical Scavenging Property of Thiomethyl Group on Met via Formatting Sulfoxonium Intermediate

To confirm the antioxidant activity of L-Met in *vitro*, we evaluated the ROS-scavenging activity of L-Met by EPR. In EPR assay, hydroxyl radical was induced by Fenton reaction and trapped by DMPO to form a stable spin adduct DMPO-OH. L-Met reduced the signal of spin adduct to 58.8%±6.1% of vehicle-treated group at 1 mmol/L (P<0.05, n=6–8, one way ANOVA, fig. 3A–3D). Meanwhile, 0.1 mmol/L L-Met could not reduce the spin adduct signal (94.1%±11.6% of vehicle, n=6, P>0.05).

To validate this hypothesis, we observed the effect of MsrA on the reaction between ROS and L-Met in *vitro* using a recombinant rat MsrA (rMsrA). In our previous study, we found that neither MsrA nor non-active MsrA alone has perceptible effects on EPR signals. EPR assay (fig. 2E–2G) showed that co-treatment of L-Met with non-active MsrA or active MsrA decreased the DMPO-OH signal amplitude to 88.6%±11.0% (P<0.05, Student’s t test, n=6–8) or 59.9%±2.6% (P<0.05, Student’s t test, n=6–8) of vehicle group in the presence of 0.1 mmol/L L-Met, respectively. Compared to non-active MsrA group, active MsrA group significantly decreased the DMPO-OH signal (P<0.01, n=6–8, Student’s t test), indicating that MsrA facilitates the reaction of L-Met and ROS.

Then, to understand how MsrA catalyzes the oxidation of L-Met, homology modeling was used to visualize structural interactions between Met and MsrA. First, we observed that L-Met could bind to the catalytic pocket of MsrA (fig. 2H). The space of the pocket was formed by the side chains of Cys72, Phe73, Trp74, Tyr103 and Glu115. Previous studies had shown that the first step of MsrA-catalytic oxidation is to form
a sulfenic acid residue on Cys72 by ROS\cite{29}. Thus, to induce the sulfoxide structure, the reaction between oxygen atom on the Cys72 (CYO\textsubscript{72}-S/-O) and S atom from substrates is the limited step. To increase the reaction rate, a preferred orientation in the pocket is required for the substrate. Thus, we analyzed the orientation of different MsrA substrates in the active site of MsrA and found that L-Met adopted a preferred orientation than most of the others with the distance of O-S 3.9 Å. We found that residues Tyr103, Glu115, Tyr155, Phe73 and Trp74 contributed to the oxidation of L-Met, especially Trp74, Tyr103 and Glu115. When L-Met bound, the distances of donor and acceptor atoms (D-H...A) between the O atom from CYO\textsubscript{72} and the H atom from Tyr103-OH and Glu115-COOH were 3.0 Å and 2.7 Å, respectively. The two hydrogen bonds helped the transfer of O atom from CYO\textsubscript{72} to the S atom from sulfide and facilitated the oxidation of L-Met.

2.3 SMLC, an L-Met Analogue and ROS Scavenger, Emerges as a Substrate of MsrA-catalytic Met Oxidase Activity

To confirm the antioxidant activity of SMLC, a hydrophilic cysteine-containing compound naturally found in garlic and onion (fig. 4A), we evaluated the ROS-scavenging activity of SMLC by EPR. In the
same experiment settings of L-Met, SMLC reduced the signal of spin adduct to 26.9%±6.7% of vehicle-treated group at 10 mmol/L (P<0.01, n=5, one way ANOVA, fig. 4B–4F). Meanwhile, 0.1 or 1 mmol/L SMLC could not reduce the spin adduct signal (98.9%±7.4% and 94.8%±10.7% of vehicle group, P>0.05).

Then we observed the effect of MsrA on the reaction between ROS and SMLC. The EPR assay showed co-treatment of 0.1 mmol/L SMLC and non-active MsrA (boiled) or active MsrA decreased the DMPO-OH signal amplitude to 64.61%±1.8% (P<0.05, n=5–7, Student’s t test, fig. 4G–4J) or 17.5%±1.7% (P<0.01, n=7–8, Student’s t test) of vehicle group in the presence of 0.1 mmol/L SMLC, respectively. Compared to non-active MsrA group, active MsrA with SMLC exerted a much better anti-oxidant activity in the Fenton system (P<0.01, n=5–8, Student’s t test), which indicated that MsrA significantly facilitates the reaction of SMLC and ROS.

2.4 SMLC Reduces Antimycin A-induced Mitochondrial Membrane Depolarization in PC12 Cells

As mitochondria are critical for apoptosis, it was logical to explore the effect of Met or SMLC on mitochondrial function. In this study, we used JC-1 as a...
fluorescent probe to detect the change in mitochondrial membrane potential by the change in fluorescence color. Compared with control group, treatment with 100 ng/mL antimycin A for 30 min led to mitochondrial membrane potential collapse as shown by enhanced red/green ratio. Then cells were pretreated with 1 mmol/L SMLC or 1 mmol/L L-Met at 0.5 h before adding antimycin A until the end. The red/green ratio was increased by SMLC or L-Met treatment (SMLC: 31.3%±4.1%, L-Met: 31.7%±4.8%, n=8, P<0.01, fig. 5) compared with antimycin A-treated vehicle group (22.4%±1.0% of control, n=5, P<0.01 vs. control).

2.5 SMLC Protects SH-SY5Y Cells against MPP+-induced Cytotoxicity

Then, we examined whether the radical-scavenging effect of L-Met and SMLC conferred neuroprotection. We used a MPP+-induced neurotoxicity model. SH-SY5Y cells were treated with 2 mmol/L MPP+ for 8, 16, 24 and 48 h. MTT assay showed that MPP+ reduced the cell viability in a time-dependent manner (fig. 6A). The cell viability decreased to 81.2%±6.4%, 55.9%±12.4% and 25.2%±4.7% of control group in 8, 16, 24 and 48 h-treated groups. Then cells were pretreated with various concentrations of L-Met at 0.5 h before adding MPP+ until the end. The cell viability was increased by L-Met treatment (0.1 mmol/L: 31.3%±4.1%, 0.5 mmol/L: 31.7%±4.8% and 1 mmol/L: 40.2%±5.6%, n=8, P<0.01 vs. control). SH-SY5Y cells were pretreated with L-Met for 0.5 h before adding MPP+. Then we tested whether SMLC could alleviate MPP+-induced neurotoxicity. Compared with MPP+-treated group (22.5%±5.3% of control, P<0.01), the cell viability was increased by SMLC treatment (0.1 mmol/L: 34.6%±4.5%, 0.5 mmol/L: 41.1%±2.7% and 1 mmol/L: 45.5%±2.5%, n=8, P<0.01 vs. control), when the cells were pretreated with various concentrations of SMLC for 0.5 h before adding MPP+ until the end. These data indicated a protective role of MsrA-catalytic Met oxidase activity initiated by L-Met and SMLC in MPP+-induced neurotoxicity.

Fig. 5 SMLC reduced antimycin-induced mitochondrial membrane depolarization in PC12 cells. A, B: PC12 cells were pretreated with 1 mmol/L SMLC or 1 mmol/L L-Met for 30 min and then incubated with antimycin A (100 μg/mL for 30 min). The mitochondrial membrane potential (JC-1 staining, red/green fluorescence ratio) was photographed and quantified by fluorescence microscopy. Data are expressed as means±SD. n=5, **P<0.01 vs. control group, ***P<0.01 vs. model group.
3 DISCUSSION

Our study provided evidence that MsrA helped L-Met and its analogue SMLC scavenge radicals via formatting sulfonium intermediate, which protected cells from oxidative stress and neutron toxin-induced neurotoxicity. With release of SMLC sulfoxide, the reduced form of MsrA is formed. After MsrA knockdown, the anti-oxidant activity of L-Met in PC12 cells was nearly abolished. Meanwhile, computational chemistry evidence showed that Met-like structure was a substrate of oxide-MsrA. We believe that the oxygen atom on the sulfenic acid was derived from ROS or radicals. A lone pair of electrons on the Met or SMLC sulfur attacked the sulfonicsulfur to form the positively charged sulfonium intermediate. Glu115 and Tyr103 acted as a proton donor and were stabilized by hydrogen bonding with SMLC (fig. 6D). These data highlight the role of MsrA in the detoxication of mitochondrial ROS-generating toxins.

Epidemiologically, environmental neurotoxins, such as pesticides, MPP+, 6-hydroxydopamine, rotenone, 3-nitropropionic acid and paraquat, induced neurotoxicity via triggering mitochondrial oxidative stress burdens\(^1-3\). Levels of ROS exceed the antioxidant capacity of the mitochondria of neurons. These neurotoxins are promising candidates for causative factors of neurodegenerative diseases, including PD. Aging-associated decline in the endogenous antioxidant defense increased the susceptibility to neurotoxins. Among the endogenous antioxidant defenses, MCRC, which depends on the anti-oxidation activity of protein-bound Met residues and their redox cycle containing Met-MetO-Met, plays a critical role in the protection
of key proteins. In the MCRC, Met residues in proteins act as a “sink” for many reactive species, and Msrs catalyze a thio-redox-dependent reduction of MetO back to Met. This cyclic interconversion of protein Met residues between oxidized and reduced forms may be considered an efficient ROS-scavenging mechanism in vivo. Although most studies have indicated a role of MCRC in the aging-related diseases, much less is known about its role in the neuro-toxicology of ROS-generating toxins. Our previous studies revealed that Met alleviates H2O2-induced mitochondrial injury and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced skin oxidation. Selective dopaminergic neuronal cell death caused by environmental neurotoxin MPP+ has been widely used as a cell model of PD. In the current study, we further observed that Met also alleviates MPP+-induced neurotoxicity of SH-SY5Y cells. All the data raised the critical role of MCRC in the detoxication of mitochondrial ROS-generating toxins.

It is conventionally believed that the mitochondrial ROS scavenging effect of MCRC is mainly due to the natural anti-oxidation activity of Met residues. Under oxidative stress, MsrA can maintain an effective concentration of Met by reducing MetO timely via activating its reductase. Our previous study found that under oxidative stress, more than 80% of protein-bound Met residues are kept in a reduced form, indicating that there is a sufficient store of Met. Although L-Met can act as an effective H2O2 scavenger in vitro in the presence of a high concentration of H2O2 (above 1 mmol/L), after inhibition of MsrA function by DMSO, the antioxidation of Met (1–5 mmol/L) on CHO cells is largely abolished. Recently, it has been demonstrated that MsrA also serves as a stereospecific methionine oxidase, which may facilitate the reaction of Met with ROS. Here, we observed that knockdown of MsrA by shRNA nearly abolished the antioxidation of Met in the mitochondrial ROS generation. In Fenton system, EPR spin-trapping assay revealed that MsrA facilitated the Met (1 mmol/L)-mediated scavenging effect on hydroxyl radicals. Thus, Met is not merely an antioxidant, and its action may require a participation of MsrA in vivo.

MsrA has historically been considered a reductase to repair damaged proteins, not an ROS scavenger. In spite of its impressive protective effects in neurotoxicity, the precise mechanisms and fundamental chemical principles for MsrA-mediated mitochondrial ROS elimination remain largely unclear. Although MsrA may exhibit antioxidant via maintaining an effective concentration of Met by reducing MetO timely, this study, together with our previous work, has demonstrated that the stereospecific Met oxidase activity may play a vital role in the anti-oxidation of MsrA, which may afford the antioxidant effect against neurotoxins, including H2O2, antimycin and MPP+. By computation, we found that the lone pair electrons on the methylthiol-sulfur nucleophilically of sulfide attacked the sulfinic sulfur in active site of MsrA to form the positively charged sulfonium intermediate. Then, MsrA catalyzed the transition and released the sulfoxide. When ROS bursted in vivo, ROS induced a sulfenic acid residue on Cys72 of MsrA, which was followed by the reaction between oxygen atom on CYO72 and S atom of DMS. The Phe73 and Trp74 in MsrA facilitated Met to bind the active center via hydrophobic bond, and Tyr103 and Glu115 increased the oxygen atom transfer from the CYO72 to the S atom of Met via the hydrogen bond. The peroxidase activity of MsrA significantly facilitated the reactivity of Met and SMLC at a relatively low concentration. The mechanisms of Met and SMLC-mediated radical-scavenging capacity were illustrated in fig. 6D.

Pharmacological enhancement of MsrA function seems to be reasonable therapeutic strategy against aging in clinical practice. Only very few approaches are available to enhance MsrA function. Comparing to the reducing activity of MsrA for repairing oxidized proteins, activation of Met oxidase activity of MsrA required a relatively high substrate concentration. To increase the concentrations of substrate, Met supplement may not be an appropriate approach, especially in aging-related diseases, like PD and AD, for Met is rapidly incorporated into proteins and it increases cardiovascular risk. In fact, dietary Met restriction, not supplementation, induces beneficial effects. For the doubtful problem for Met supplementation, other Met analogs could be considered. SMLC is a safe sulfur containing amino acid naturally found in garlic and onion, which has been reported to have anti-lipidemic activity and anti-PD effects in Drosophila. We found that SMLC exerted a better natural anti-oxidant activity and its anti-oxidation was also facilitated by MsrA. SMLC works as a substrate in the Met oxidase activity of MsrA. Moreover, it exerted a good neuroprotection in MPP+-induced injury in SH-SY5Y cells. However, more in vivo evidence to support this view is still required. Whether dietary supplementation with SMLC or L-Met in humans is applicable remains to be tested.

In summary, our data supported that the Met oxidase activity of MsrA might be targeted therapeutically to prevent mitochondrial ROS-generating toxins and aging-associated neurodegenerative diseases by activators like SMLC in the future.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
Conflict of Interest Statement

The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.

REFERENCES

1. Chan MC, Bautista E, Alvarado-Cruz I, et al. Inorganic mercury prevents the differentiation of SH-SY5Y cells: Amyloid precursor protein, microtubule associated proteins and ROS as potential targets. J Trace Elem Med Bio, 2017,41:119-128
2. Cabezas R, Vega-Vela NE, Gonzalez-Sanniguel J, et al. PDGF-BB Preserves Mitochondrial Morphology, Attenuates ROS Production, and Uregulates Neuroglobin in an Astrocytic Model Under Rotenone Insult. Mol Neurobiol, 2018,55(4):3085-3095
3. Gao C, Chang P, Yang L, et al. Neuroprotective effects of hydrogen sulfide on sodium azide-induced oxidative stress in PC12 cells. Int J Mol Med, 2018,41(1):242-250
4. Kaneko YS, Ota A, Nakashima A, et al. Regulation of oxidative stress in long-lived lipopolysaccharide-activated microglia. Clin Exp Pharmacol Physiol, 2012, 39(7):599-607
5. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci U S A, 2003,100(10):6145-6150
6. Oyewole AO, Birch-Machin MA. Mitochondria-targeted antioxidants. FASEB J, 2015,29(12):4766-4771
7. Feniouk BA, Skulachev VP. Cellular and Molecular Mechanisms of Action of Mitochondria-Targeted Antioxidants. Curr Aging Sci, 2017,10(1):41-48
8. Genet N, Billaud M, Rossignol R, et al. Signaling Pathways Linked to Serotonin-Induced Superoxide Anion Production: A Physiological Role for Mitochondria in Pulmonary Arteries. Front Physiol, 2017,8:76
9. Wu ZF, Zhang J, Zhao BL. Superoxide Anion Regulates the Mitochondrial Free Ca2+ through Uncoupling Proteins. Antioxid Redox Sign, 2009,11(8):1805-1818
10. Li Z, Ji GC, Neugebauer V. Mitochondrial Reactive Oxygen Species Are Activated by mGluR5 through IP3 and Activate ERK and PKA to Increase Excitability of Amygdala Neurons and Pain Behavior. J Neurosci, 2011,31(3):1114-1127
11. Liu M, Liu H, Dudley SC. Reactive Oxygen Species Originating From Mitochondria Regulate the Cardiac Sodium Channel. Circ Res, 2010,107(8):967-974
12. Hou Y, Ouyang X, Wan R, et al. Mitochondrial superoxide production negatively regulates neural progenitor proliferation and cerebral cortical development. Stem Cells, 2012,30(11):2535-2547
13. Mailloux RJ. Mitochondrial Antioxidants and the Maintenance of Cellular Hydrogen Peroxide Levels. Oxid Med Cell Longev, 2018,2018:7857251
14. Stadtman ER, Moskovitz J, Berlett BS, et al. Cyclic oxidation and reduction of protein methionine residues is an important antioxidant mechanism. Mol Cell Biochem, 2002,234(1):3-9
15. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta, 2005,1703(2):93-109
16. Luo S, Levine RL. Methionine in proteins defends against oxidative stress. FASEB J, 2009,23(2):464-472
17. Wood JM, Decker H, Hartmann H, et al. Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J, 2009,23(7):2065-2075
18. Hansel A, Kuschel L, Heh S, et al. Mitochondrial targeting of the human peptide methionine sulfoxide reductase (MSRA), an enzyme involved in the repair of oxidized proteins. FASEB J, 2002,16(8):911-913
19. Vougiou S, Mary J, Friguet B. Subcellular localization of methionine sulfoxide reductase A (Msra): evidence for mitochondrial and cytosolic isoforms in rat liver cells. Biochem J, 2003,373:531-537
20. Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: role of Msra and other repair systems in cataract and macular degenerations. Exp Eye Res, 2009,88(2):195-203
21. Picot CR, Petropoulos I, Perichon M, et al. Overexpression of Msra protects WI-38 SV40 human fibroblasts against H2O2-mediated oxidative stress. Free Radic Biol Med, 2005,39(10):1332-1341
22. Liu F, Hindupur J, Nguyen JL, et al. Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson’s disease-related insults. Free Radical Bio Med, 2008,45(3):242-255
23. Cabreiro F, Picot CR, Perichon M, et al. Overexpression of Methionine Sulfoxide Reductases A and B Protects MOLT-4 Cells Against Zinc-Induced Oxidative Stress. Antioxid Redox Sign, 2009,11(2):215-225
24. Zhang C, Jia PP, Jia YY, et al. Methionine Sulfoxide Reductase A (Msra) Protects Cultured Mouse Embryonic Stem Cells From H2O2-Mediated Oxidative Stress. J Cell Biochem, 2010,111(1):94-103
25. Singh MP, Kwak GH, Kim KY, et al. Methionine sulfoxide reductase A protects hepatocytes against acetaminophen-induced toxicity via regulation of thioredoxin reductase 1 expression. Biochem Biophys Res Commun, 2017,487(3):695-701
26. Moskovitz J, Berlett BS, Poston JM, et al. The yeast peptide methionine sulfoxide reductase functions as an antioxidant in vivo. P Natl Acad Sci USA, 1997,94(18):9585-9589
27. Moskovitz J, Du F, Bowman CF, et al. Methionine sulfoxide reductase A affects beta-amyloid solubility and mitochondrial function in a mouse model of Alzheimer’s disease. Am J Physiol Endocrinol Metab, 2016,310(6):E388-E393
28. Fan H, Wu PF, Zhang L, et al. Methionine sulfoxide reductase A negatively controls microglia-mediated neuroinflammation via inhibiting ROS/MAPKs/ NF-kappaB signaling pathways through a catalytic antioxidant function. Antioxid Redox Signal, 2015, 22(10):832-847
29 Guan XL, Wu PF, Wang S, et al. Dimethyl sulfide protects against oxidative stress and extends lifespan via a methionine sulf oxide reductase A-dependent catalytic mechanism. Aging Cell, 2017,16(2):226-236
30 Hirche F, Schroder A, Knoth B, et al. Methionine-induced elevation of plasma homocysteine concentration is associated with an increase of plasma cholesterol in adult rats. Ann Nutr Metab, 2006,50(2):139-146
31 Virtanen JK, Voutilainen S, Rissanen TH, et al. High dietary methionine intake increases the risk of acute coronary events in middle-aged men. Nutr Metab Cardiovas, 2006,16(2):113-120
32 Eyre MD, Phillips DE, Evans IM, et al. The nutritional role of S-Methyl-L-cysteine. J Sci Food Agric, 1983,34(7):696-700
33 Takada N, Yano Y, Wanibuchi H, et al. S-methylcysteine and cysteine are inhibitors of induction of glutathione S-transferase placental form-positive foci during initiation and promotion phases of rat hepatocarcinogenesis. Jpn J Cancer Res, 1997,88(5):435-442
34 Yeh YY, Liu LJ. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: Human and animal studies. J Nutr, 2001,131(3):989s-993s
35 Hsu CC, Yen HF, Yin MC, et al. Five cysteine-containing compounds delay diabetic deterioration in Balb/c a mice. J Nutr, 2004,134(12):3245-3249
36 Wassif R, Haenold R, Hansel A, et al. Methionine sulfoxide reductase A and a dietary supplement S-Methyl-L-cysteine prevent Parkinson’s-Like symptoms. J Neurosci, 2007,27(47):12808-12816
37 Wu PF, Xie N, Zhang JJ, et al. Resveratrol preconditioning increases methionine sulf oxide reductases A expression and enhances resistance of human neuroblastoma cells to neurotoxins. J Nutr Biochem, 2013,24(6):1070-1077
38 Wu WN, Wu PF, Chen XL, et al. Sinomoreine protects against ischemic brain injury: involvement of co-inhibition of acidic-sensing ion channel 1a and L-type calcium channels. Br J Pharmacol, 2011,164(5):1445-1459
39 Lindorff-Larsen K, Piana S, Palmo K, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins, 2010,78(8):1950-1958
40 Bulvik B, Grinberg L, Eliahar R, et al. Iron, ferritin and proteins of the methionine-centered redox cycle in young and old rat hearts. Mech Ageing Dev, 2009,130(3):139-144
41 Vinokur V, Grinberg L, Berenshtein E, et al. Methionine-centered redox cycle in organs of the aero-digestive tract of young and old rats. Biogerontology, 2009,10(1):43-52
42 Wu PF, Long LH, Zeng JH, et al. Protection of L-methionine against H2O2-induced oxidative damage in mitochondria. Food Chem Toxicol, 2012,50(8):2729-2735
43 Long LH, Wu PF, Guan XL, et al. Determination of protein-bound methionine oxidation in the hippocampus of adult and old rats by LC-ESI-ITMS method after microwave-assisted proteolysis. Anal Bioanal Chem, 2011,399(6):2267-2274
44 Lim JC, You Z, Kim G, et al. Methionine sulfoxide reductase A is a stereospecific methionine oxidase. P Natl Acad Sci USA, 2011,108(26):10472-10477
45 Tarrago L, Kaya A, Weerapana E, et al. Methionine Sulfoxide Reductases Preferentially Reduce Unfolded Oxidized Proteins and Protect Cells from Oxidative Protein Unfolding. J Biol Chem, 2012,287(29):24448-24459
46 Moskovitz J, Maiti P, Lopes DH, et al. Induction of methionine-sulfoxide reductases protects neurons from amyloid beta-protein insults in vitro and in vivo. Biochemistry, 2011,50(49):10687-1097
47 Minnitti AN, Arrazola MS, Bravo-Zehnder M, et al. The Protein Oxidation Repair Enzyme Methionine Sulfoxide Reductase A Modulates A beta Aggregation and Toxicity In Vivo. Antioxid Redox Sign, 2015,22(1):48-62
48 Novoselov SV, Kim HY, Hua D, et al. Regulation of selenoproteins and methionine sulfoxide reductases A and B1 by age, calorie restriction, and dietary selenium in mice. Antioxid Redox Signal, 2010,12(7):829-838
49 Cudic P, Joshi N, Sagher D, et al. Identification of activators of methionine sulfoxide reductases A and B. Biochem Bioph Res Co, 2016,469(4):863-867
50 Malloy VL, Krajcik RA, Bailey SJ, et al. Methionine restriction decreases visceral fat mass and preserves insulin action in aging male Fischer 344 rats independent of energy restriction. Aging Cell, 2006,5(4):305-314
51 Thomas S, Senthilkumar GP, Sivaraman K, et al. Effect of S-Methyl-L-Cysteine on Oxidative Stress, Inflammation and Insulin Resistance in Male Wistar Rats Fed with High Fructose Diet. Iran J Med Sci, 2015,40(1):45-50

(Received June 1, 2020; revised June 30, 2020)